How early-stage diversity strategies can save time and budget later

Xoli Belgrave, Head of Clinical Trial Diversity, Equity and Inclusion at Parexel explains why it's important for sponsors to create a diversity strategy early in clinical development to minimize the need for rework later.

Return to Insights Center

Related Insights

Article

Can Chinese Phase I data from the West accelerate China drug development?

Mar 17, 2021

Blog

Xoli Belgrave appointed to lead Parexel’s Clinical Trial Diversity, Equity & Inclusion strategy

Jan 10, 2023

Webinar

In Conversation: Leadership Lessons on Diversity, Equity, & Inclusion, and the Future of Work

Apr 29, 2021

Video

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Jun 8, 2021

Article

3 ways to incorporate DE&I in your communications strategy

Sep 29, 2021

Blog

CNS Summit Recap: The Future is Collaborative

Nov 22, 2021

Blog

Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity

Mar 3, 2022

Podcast

Decentrally Speaking | Episode 1: Optimizing Trial Inclusivity For Patients From Under-Represented Communities

Mar 22, 2022

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022

Blog

Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients

Sep 23, 2022

Webinar

Accelerating early phase development in the UK and Germany

Apr 5, 2024

Blog

Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines

Apr 4, 2024